These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 34412102)
41. Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view. Varnai R; Szabo I; Tarlos G; Szentpeteri LJ; Sik A; Balogh S; Sipeky C Pharmacogenomics J; 2020 Jun; 20(3):380-387. PubMed ID: 31787752 [TBL] [Abstract][Full Text] [Related]
43. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Swen JJ; van der Wouden CH; Manson LE; Abdullah-Koolmees H; Blagec K; Blagus T; Böhringer S; Cambon-Thomsen A; Cecchin E; Cheung KC; Deneer VH; Dupui M; Ingelman-Sundberg M; Jonsson S; Joefield-Roka C; Just KS; Karlsson MO; Konta L; Koopmann R; Kriek M; Lehr T; Mitropoulou C; Rial-Sebbag E; Rollinson V; Roncato R; Samwald M; Schaeffeler E; Skokou M; Schwab M; Steinberger D; Stingl JC; Tremmel R; Turner RM; van Rhenen MH; Dávila Fajardo CL; Dolžan V; Patrinos GP; Pirmohamed M; Sunder-Plassmann G; Toffoli G; Guchelaar HJ; Lancet; 2023 Feb; 401(10374):347-356. PubMed ID: 36739136 [TBL] [Abstract][Full Text] [Related]
44. Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx). Picard N; Boyer JC; Etienne-Grimaldi MC; Barin-Le Guellec C; Thomas F; Loriot MA; Therapie; 2017 Apr; 72(2):185-192. PubMed ID: 28237406 [TBL] [Abstract][Full Text] [Related]
45. Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands. Bank PCD; Swen JJ; Guchelaar HJ BMC Med; 2019 Jun; 17(1):110. PubMed ID: 31196067 [TBL] [Abstract][Full Text] [Related]
47. Pharmacogenetics implementation in the clinics: information and guidelines for germline variants. Olivera G; Sendra L; Herrero MJ; Berlanga P; Gargallo P; Yáñez Y; Urtasun A; de Mora JF; Castel V; Cañete A; Aliño SF Cancer Drug Resist; 2019; 2(1):53-68. PubMed ID: 35582138 [TBL] [Abstract][Full Text] [Related]
49. Clinical implementation of genetic testing in medicine: a US regulatory science perspective. Lesko LJ; Schmidt S Br J Clin Pharmacol; 2014 Apr; 77(4):606-11. PubMed ID: 24286486 [TBL] [Abstract][Full Text] [Related]
50. Strategies and settings of clinical pharmacogenetic implementation: a scoping review of pharmacogenetics programs. Luczak T; Brown SJ; Armbruster D; Hundertmark M; Brown J; Stenehjem D Pharmacogenomics; 2021 Apr; 22(6):345-364. PubMed ID: 33829852 [TBL] [Abstract][Full Text] [Related]
51. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Caudle KE; Dunnenberger HM; Freimuth RR; Peterson JF; Burlison JD; Whirl-Carrillo M; Scott SA; Rehm HL; Williams MS; Klein TE; Relling MV; Hoffman JM Genet Med; 2017 Feb; 19(2):215-223. PubMed ID: 27441996 [TBL] [Abstract][Full Text] [Related]
52. Pharmacogenetics in Practice: Estimating the Clinical Actionability of Pharmacogenetic Testing in Perioperative and Ambulatory Settings. Smith DM; Peshkin BN; Springfield TB; Brown RP; Hwang E; Kmiecik S; Shapiro R; Eldadah Z; Lundergan C; McAlduff J; Levin B; Swain SM Clin Transl Sci; 2020 May; 13(3):618-627. PubMed ID: 31961467 [TBL] [Abstract][Full Text] [Related]
53. Pharmacogenetics of anti-cancer drugs: State of the art and implementation - recommendations of the French National Network of Pharmacogenetics. Quaranta S; Thomas F Therapie; 2017 Apr; 72(2):205-215. PubMed ID: 28262261 [TBL] [Abstract][Full Text] [Related]
54. Personalizing medicine with clinical pharmacogenetics. Scott SA Genet Med; 2011 Dec; 13(12):987-95. PubMed ID: 22095251 [TBL] [Abstract][Full Text] [Related]
55. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Caudle KE; Klein TE; Hoffman JM; Muller DJ; Whirl-Carrillo M; Gong L; McDonagh EM; Sangkuhl K; Thorn CF; Schwab M; Agundez JA; Freimuth RR; Huser V; Lee MT; Iwuchukwu OF; Crews KR; Scott SA; Wadelius M; Swen JJ; Tyndale RF; Stein CM; Roden D; Relling MV; Williams MS; Johnson SG Curr Drug Metab; 2014 Feb; 15(2):209-17. PubMed ID: 24479687 [TBL] [Abstract][Full Text] [Related]
56. [Recommendations for performing pharmacogenetic tests in drug monographs in Canada, France and the United States]. Marquot G; Frison C; Lebel D; Bussières JF; Métras MÉ Ann Pharm Fr; 2020 Sep; 78(5):447-457. PubMed ID: 32777298 [TBL] [Abstract][Full Text] [Related]
57. Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population. Lee YM; Manzoor BS; Cavallari LH; Nutescu EA Pharmacotherapy; 2018 Feb; 38(2):205-216. PubMed ID: 29286540 [TBL] [Abstract][Full Text] [Related]
58. Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions. Reisberg S; Krebs K; Lepamets M; Kals M; Mägi R; Metsalu K; Lauschke VM; Vilo J; Milani L Genet Med; 2019 Jun; 21(6):1345-1354. PubMed ID: 30327539 [TBL] [Abstract][Full Text] [Related]
59. Pharmacogenetic and pharmacogenomic considerations of asthma treatment. Matera MG; Rinaldi B; Calzetta L; Cazzola M Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1159-1167. PubMed ID: 28992739 [TBL] [Abstract][Full Text] [Related]
60. The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later. Relling MV; Klein TE; Gammal RS; Whirl-Carrillo M; Hoffman JM; Caudle KE Clin Pharmacol Ther; 2020 Jan; 107(1):171-175. PubMed ID: 31562822 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]